Betavog-GM 2
Glimepiride, Voglibose & Metformin Hydrochloride (SR) Tablets
“ Triple Control. Better Diabetes Management. ”
Product Overview
BETAVOG-GM2 Tablets are a triple-action oral anti-diabetic formulation specially designed for the effective management of Type 2 Diabetes Mellitus. The synergistic combination of Glimepiride, Voglibose, and Metformin Hydrochloride (Sustained Release) provides comprehensive glycemic control by stimulating insulin secretion, delaying carbohydrate absorption, and reducing hepatic glucose production.
🔬 Mechanism of Action (Ingredients)
✦ Glimepiride (2 mg)
- Stimulates pancreatic beta-cells to trigger healthy insulin secretion.
- Lowers both fasting and post-meal (postprandial) glucose ranges effectively.
✦ Voglibose (0.2 mg)
- Acts as a selective alpha-glucosidase inhibitor inside the intestinal lining.
- Delays carbohydrate digestion, avoiding sudden glucose spikes after food consumption.
✦ Metformin Hydrochloride (Sustained Release - 500 mg)
- Suppresses excess hepatic gluconeogenesis (glucose manufacture by liver).
- Enhances insulin receptor sensitivity in peripheral skeletal muscle tissues.
- Sustained-release matrix ensures uniform therapeutic distribution and minimal digestive side-effects.
🎯 Approved Clinical Indications
• Type-2 Diabetes Mellitus
• Poor Glycemic Index Controls
• Elevated Fasting Blood Glucose (FBG)
• Postprandial Hyperglycemia spikes
• Severe Insulin Resistance
• Patients requiring triple-combination therapy
📦 Product Packaging
📊 Clinical Efficacy & Study Data
Comparative clinical charts derived from pharmacokinetics data showing efficacy parameters.